

Bristol-Myers Squibb Pharmaceuticals

A Division of Bristol-Myers Squibb Australia Pty. Ltd. A.B.N. 33 004 333 322

P.O. Box 39 556 Princes Highway Noble Park North, Victoria 3174 Australia Tel: (03) 9213 4000 International: +61-3-9213 4000

Fax: International: (+61-3) Managing Director: (03) 9701 1524 Sales & Marketing: (03) 9701 1526 Finance: (03) 9701 1334 Technical Operations: (03) 9795 0968
Human Resources Division: (03) 9795 6182

Pharmaceutical Research Institute (P.R.I.): (03) 9701 1519 Medical Department: (03) 9701 1508 Regulatory Affairs (03) 9795 6107 Export: (03) 9701 1312

8 November 2006

Dear Hospital Pharmacist

Perfalgan® (IV paracetamol) rubber bungs

Perfalgan® (IV paracetamol) rubber bungs (stoppers) are compliant with the European Pharmacopeia (EP) and AFNOR ISO 8536-2:2001 recommendations. Based on EP testing standards, a syringe with a diameter equal or below 0.8 mm should be used for solution sampling.

In addition, we recommend that the bung is pierced vertically (angle of 90° between the needle and the bung) and at the locations specifically designed for needle introduction (where the thickness of the bung is the lowest).

If these recommendations are not adhered to, the likelihood of bung fragmentation or the bung being forced into the vial is increased.

Yours sincerely



Heath Merlo

Associate Product Manager



A Bristol-Myers Squibb Company